MicroRNA‐122 and cytokeratin‐18 have potential as a biomarkers of drug‐induced liver injury in European and African patients on treatment for mycobacterial infection

AIMS: Patients on antituberculosis (anti‐TB) therapy are at risk of drug‐induced liver injury (DILI). MicroRNA‐122 (miR‐122) and cytokeratin‐18 (K18) are DILI biomarkers. To explore their utility in this global context, circulating miR‐122 and K18 were measured in UK and Ugandan populations on anti‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Rupprechter, Sarah A.E., Sloan, Derek J., Oosthuyzen, Wilna, Bachmann, Till T., Hill, Adam T., Dhaliwal, Kevin, Templeton, Kate, Matovu, Joshua, Sekaggya‐Wiltshire, Christine, Dear, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629110/
https://www.ncbi.nlm.nih.gov/pubmed/33432705
http://dx.doi.org/10.1111/bcp.14736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629110/
https://www.ncbi.nlm.nih.gov/pubmed/33432705
http://dx.doi.org/10.1111/bcp.14736

Ejemplares similares